$1.5 Billion is the total value of Eversept Partners, LP's 87 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QQQ | New | INVESCO QQQ TRput | $88,607,500 | – | 250,000 | +100.0% | 5.91% | – |
| BIIB | New | BIOGEN INCcall | $40,028,812 | – | 115,600 | +100.0% | 2.67% | – |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $31,961,877 | – | 478,328 | +100.0% | 2.13% | – |
| XBI | New | SPDR SER TRcall | $27,080,000 | – | 200,000 | +100.0% | 1.80% | – |
| OGN | New | ORGANON & CO | $21,172,801 | – | 699,696 | +100.0% | 1.41% | – |
| ARKG | New | ARK ETF TRcall | $18,407,500 | – | 199,000 | +100.0% | 1.23% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $17,631,380 | – | 442,000 | +100.0% | 1.18% | – |
| RCM | New | R1 RCM INC | $17,124,800 | – | 770,000 | +100.0% | 1.14% | – |
| HQY | New | HEALTHEQUITY INC | $15,894,800 | – | 197,500 | +100.0% | 1.06% | – |
| AMN | New | AMN HEALTHCARE SVCS INC | $15,429,615 | – | 159,101 | +100.0% | 1.03% | – |
| OMCL | New | OMNICELL COM | $14,897,531 | – | 98,366 | +100.0% | 0.99% | – |
| XBI | New | SPDR SER TRput | $13,540,000 | – | 100,000 | +100.0% | 0.90% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $10,988,835 | – | 54,500 | +100.0% | 0.73% | – |
| TIP | New | ISHARES TRput | $8,960,700 | – | 70,000 | +100.0% | 0.60% | – |
| TDOC | New | TELADOC HEALTH INCcall | $6,651,600 | – | 40,000 | +100.0% | 0.44% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB Lcall | $6,554,800 | – | 70,000 | +100.0% | 0.44% | – |
| OPCH | New | OPTION CARE HEALTH INC | $6,326,925 | – | 289,297 | +100.0% | 0.42% | – |
| OM | New | OUTSET MED INC | $5,362,854 | – | 107,300 | +100.0% | 0.36% | – |
| CGEM | New | CULLINAN ONCOLOGY INC | $4,219,910 | – | 163,880 | +100.0% | 0.28% | – |
| MRK | New | MERCK & CO INCcall | $3,787,399 | – | 48,700 | +100.0% | 0.25% | – |
| EXEL | New | EXELIXIS INC | $3,279,600 | – | 180,000 | +100.0% | 0.22% | – |
| MRVI | New | MARAVAI LIFESCIENCES HLDGS I | $3,129,750 | – | 75,000 | +100.0% | 0.21% | – |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $3,141,211 | – | 473,074 | +100.0% | 0.21% | – |
| IPSC | New | CENTURY THERAPEUTICS INC | $2,960,435 | – | 100,901 | +100.0% | 0.20% | – |
| HSTM | New | HEALTHSTREAM INC | $2,174,067 | – | 77,812 | +100.0% | 0.14% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $2,127,000 | – | 150,000 | +100.0% | 0.14% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDcall | $1,909,710 | – | 192,900 | +100.0% | 0.13% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INput | $1,400,800 | – | 40,000 | +100.0% | 0.09% | – |
| FSTX | New | F-STAR THERAPEUTICS INC | $859,000 | – | 100,000 | +100.0% | 0.06% | – |
| BIIB | New | BIOGEN INCput | $692,540 | – | 2,000 | +100.0% | 0.05% | – |
| CCRN | New | CROSS CTRY HEALTHCARE INC | $508,673 | – | 30,810 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMARIN CORP PLC | 21 | Q3 2023 | 12.5% |
| DANAHER CORPORATION | 21 | Q3 2023 | 8.1% |
| AFFIMED N V | 20 | Q3 2023 | 0.9% |
| ARGENX SE | 19 | Q3 2023 | 2.0% |
| GSK PLC | 18 | Q2 2022 | 13.1% |
| ASCENDIS PHARMA A/S | 18 | Q1 2022 | 7.7% |
| SANOFI | 18 | Q4 2022 | 7.2% |
| ENSIGN GROUP INC | 18 | Q1 2022 | 8.6% |
| CENTENE CORP DEL | 18 | Q3 2023 | 1.5% |
| ZOGENIX INC | 17 | Q4 2021 | 12.4% |
View Eversept Partners, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cabaletta Bio, Inc. | February 14, 2023 | 282,874 | 1.0% |
| Teligent, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| Teligent, Inc. | February 14, 2020 | 4,501,799 | 8.4% |
View Eversept Partners, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
View Eversept Partners, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.